Trial Profile
A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Regorafenib
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms COTEZO; IMblaze370
- Sponsors Roche
- 30 Oct 2022 Results of pooled analysis form NCT03178851, NCT01689519, NCT02322814, and NCT02788279 of safety analysis, published in the Drug Safety
- 03 Jul 2021 Results constructing hybrid control for the Morpheus metastatic colorectal cancer trial using IMblaze370 historical trial data presented at the 23rd World Congress on Gastrointestinal Cancer
- 04 Jul 2020 Results (n=296), of exploratory post-hoc biomarker analysis presented at the 22nd World Congress on Gastrointestinal Cancer